The US Food and Drug Administration appears poised to continue with a plan to ban prescription fluoride supplements at a time ...

Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials. Read my analysis ...

United Bankshares, Inc. (NASDAQ: UBSI) ("United"), today reported record earnings for the second quarter of 2025 of $120.7 million, or $0.85 per diluted share. Second quarter of 2025 results produced ...

Cadence Bank (NYSE: CADE) (the Company), today announced financial results for the quarter ended June 30, 2025.Highlights for the ...

Identifying the correct uveitis type can help reveal underlying systemic infections, neoplastic conditions, and other ...